Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Ibrahim AldossSalman OtoukeshJianying ZhangSally MokhtariDat NgoMona MojtahedzadehMonzr M Al MalkiAmandeep SalhotraHaris AliAhmed AribiKaramjeet S SandhuShukaib ArslanPaul KollerBrian BallForrest StewartPeter CurtinAndrew ArtzRyotaro NakamuraGuido MarcucciStephen J FormanAnthony S SteinVinod PullarkatPublished in: Cancer (2021)
Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites. Most extramedullary failure cases retain CD19 expression.